Next Article in Journal
Comparison of Demographics and Oxford Knee Score in Total Knee Arthroplasty Patients Between the United Kingdom and Saudi Arabia: A Cohort Study
Previous Article in Journal
Enhancing Safety and Quality of Cardiopulmonary Resuscitation During Coronavirus Pandemic
Previous Article in Special Issue
Pharmacological Management of Transthyretin Amyloid Cardiomyopathy: Where We Are and Where We Are Going
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 14
Issue 12
10.3390/jcm14124146
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies

by
Ping Zhou
1,
Mahesh M. Mansukhani
2,
Raymond Yeh
2,
Jiesheng Lu
2,
Hongai Xia
2,
Lahari Koganti
2,
Jiuhong Pang
2,
Denis Toskic
1,
Stephanie Scalia
1,
Xun Ma
1,
Lisa X. Lee
3,
Sandy W. Wong
4,
Alfred Chung
4,
Sascha A. Tuchman
5,
Terry Fogaren
1,6,
Nancy Coady Lyons
1,6,
Cindy Varga
1,6,
Suzanne Lentzsch
7 and
Raymond L. Comenzo
1,6,*
1
The Tufts Medicine Myeloma and Amyloid Program, Tufts Medical Center, 800 Washington Street, P.O. Box 826, Boston, MA 02111, USA
2
Columbia University Laboratory of Personalized Genomic Medicine, Department of Pathology & Cell Biology, Columbia University Irving Medical Center (CUIMC), New York, NY 10032, USA
3
Chao Family Comprehensive Cancer Center, University of California, Orange, Irvine, CA 92617, USA
4
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA
5
Multiple Myeloma and Amyloidosis Program, Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA
6
Division of Hematology-Oncology, Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA
7
Multiple Myeloma and Amyloidosis Service, CUIMC, New York, NY 10032, USA
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2025, 14(12), 4146; https://doi.org/10.3390/jcm14124146
Submission received: 14 May 2025 / Revised: 2 June 2025 / Accepted: 4 June 2025 / Published: 11 June 2025
(This article belongs to the Special Issue Advances in Diagnosis and Treatment of Amyloidosis)
Browse Figure
Versions Notes

Abstract

:
Background/Objectives: To reduce the early mortality of light-chain amyloidosis (AL), earlier diagnosis is needed. To pursue this goal, we conducted a multicenter study screening for AL λ-type (NCT04615572) in subjects > 60 years of age with λ smoldering myeloma (SMM) or monoclonal gammopathy of undetermined significance (MGUS), a light-chain differential (dFLC, λ minus κ) > 23 mg/L, and no prior amyloid diagnosis. Methods: Variables included AL-related IGVL gene usage and clonal plasma cell cytogenetic abnormalities, such as t(11;14) or gain 1q, which are present in 75% of AL cases. Here, 9 out of 33 λ IGVL genes, accounting for 90% of AL λ cases, were considered to be AL-related. Bone marrow was obtained, plasma cell cytogenetics and next generation sequencing for IGVL genes were performed, and subjects with AL-related IGVL genes were screened for AL using tissue studies. Results: From 2021 to 2023, we enrolled 30 subjects (19 M/11 F) with a median age of 68.5 years old (IQR 64.3–73), 17 SMM and 13 MGUS, with a median of 6% marrow plasma cells (range, 3.5–40). Here, 11 SMM and 4 MGUS cases had t(11;14) or gain 1q; 10/17 SMM and 12/13 MGUS had AL-related genes, and AL was ultimately confirmed by tissue biopsy in 3 with SMM. SMM, AL-related IGVL genes, and t(11;14) or gain 1q were found in 6 SMM subjects, including the 3 with AL (3/6 vs. 0/16; p < 0.05, Fisher’s exact, two-tailed). Conclusions: These results justify a larger study screening for AL in SMM to develop a likelihood algorithm for AL using dFLC, IGVL gene usage, and the presence of t(11;14) or gain 1q.

1. Introduction

Delays in the diagnosis of AL occur even in patients with SMM, a known risk factor for the disease. Early diagnosis is critical given the frequency of early cardiac death and the availability of effective therapies [1,2,3]. SMM patients have an M-protein of >3 g/dL or >10% clonal plasma cells in the marrow, without myeloma-related end-organ damage. They are monitored expectantly for progression to MM requiring treatment. Progression to AL is not a reliable focus of expectant observation, and AL diagnosis is often too late [4,5,6]. In the USA, in 2023, the American Cancer Society estimated there would be 35,730 new cases of MM. Of them, 15% would have SMM, 2% of whom would progress to AL; in time, 12% to 15% of MM patients will develop AL. Nevertheless, patients with SMM continue to have delays in the diagnosis of AL. Experienced hematologists looking after patients with SMM who develop dyspnea, lower extremity edema, postural symptoms, and weight loss often refer them to other specialists who routinely miss the diagnosis of AL [7,8,9].
This is particularly troubling because the presence of a monoclonal gammopathy can be a precursor phase to AL, and without early recognition, the organ disease can progress rapidly [9]. In a study employing pre-diagnostic specimens from members of the US Armed Forces (DoD) subsequently diagnosed with systemic AL amyloidosis, investigators showed that for a decade prior to diagnosis, 80% had monoclonal serum free light-chain (FLC) abnormalities [10]. This precursor phase is characterized by the presence of a monoclonal gammopathy with differential free light-chain values (involved—uninvolved = dFLC) > 23 mg/L [10,11,12]. In the DoD series, upon diagnosis of AL, 55% of patients had cardiac involvement, a harbinger of mortality [10]. Of such cases, 20% of patients die within 6 months despite treatment, an outcome that has not improved in 40 years [13]. Moreover, in a multivariate analysis of risk factors for cardiac-related mortality in newly diagnosed AL patients, older age significantly predicted risk of death [14]. Of note, the median age at diagnosis in patients with AL is 63 years [15].
In a pilot internet-based study screening for AL in patients with λ monoclonal gammopathies, we identified undiagnosed AL in 2 of 19 subjects with SMM using dFLC and AL-related IGVL as screening variables [12]. In this multicenter study, we used the presence of AL-related IGVL genes to screen for the presence of AL in patients > 60 years of age with λ SMM and λ MGUS with a dFLC > 23 mg/L. We also gathered data on the cytogenetic abnormalities t(11;14) and gain 1q frequently found in AL. We chose to focus this study on AL λ-type because λ-type is 3× more common than κ-type.

2. Patients and Methods

2.1. Patients

To be eligible for this multi-center study (NCT04615572), subjects had to be 60 years of age or older and had to have λ isotype SMM or MGUS with the difference between λ and κ FLC > 23 mg/L, a κ:λ FLC ratio below 0.26 and no prior biopsies showing amyloid. In patients with eGFR < 50, the κ:λ FLC ratio criterion was waived because clearance of κ FLC decreases as renal function worsens, increasing the κ FLC levels in the blood and increasing the ratio [16]. The criteria for MGUS were a monoclonal protein (M-protein) and < 10% marrow plasma cells and for SMM an M-protein of >3 g/dL or >10% clonal marrow plasma cells and, in both cases, no myeloma-related end-organ damage. Cytogenetic studies were performed locally at the collaborating centers, enabling the identification of t(11;14) and gain 1q with the marrow cells obtained upon enrollment.
The aims of the study were to determine the likelihood of having AL in patients with λ MGUS or λ SMM by screening for dFLC > 23 mg/L and AL-related IGVL identification leading to tissue biopsy. We also obtained cytogenetic results for the presence of t(11;14) and gain 1q. In addition, we sought to determine if marrow mononuclear cells were adequate for λ IGVL germline gene identification by next generation sequencing compared to immunomagnetically selected plasma cells (CD138-selection). Standard epidemiologic and clinical laboratory and bone marrow data were also obtained.

2.2. IGVL Gene Identification

λ IGVL identification was performed on the Illumina platform in the Columbia University Irving Medical Center (CUIMC) Personalized Genomic Medicine Laboratory using 9 variable region and 2 constant region primers. The resulting PCR products were sheared by ultrasonication and, following end-repair and adapter ligation, sequenced on a MISeq (Illumina, San Diego, CA, USA) using a 300-cycle paired-end flow cell. After demultiplexing, Fastq files were converted to FASTA sequences and mapped for IGVL segments using IMGT (the international ImMunoGeneTics information system)-Quest to obtain clonal reads. We also performed RT-PCR for λ IGVL identification with CD138-selected cell cDNA, as previously described and used IMGT search functions for IGVL gene identification [17]. In 2020, the determination that a set of 9 of 33 λ IGVL genes were AL-related, covering over 90% of AL cases, was based on the data in AL-Base at that time (AL-Base is a platform analysis tool for the study of amyloid-forming immunoglobulin light-chain sequences [18]).

2.3. Biostatistics

Statistical analyses were performed with Graphpad Prism V5 (GraphPad, San Diego, CA, USA).

3. Results

3.1. Patients

From mid-2021 to early 2023, we enrolled 30 subjects. We initially aimed for 50 subjects, but the pandemic and funding limited presented limitations. Instead, 19 M/11 F with a median age of 68.5 years (58–92) completed the assessment of marrow specimens (Table 1).

3.2. Marrow Findings

Seventeen subjects with SMM had a median of 10.5% clonal plasma cells (range, 10–40%) and eleven had t(11;14) or gain 1q. Thirteen subjects with MGUS had a median of 5.5% clonal plasma cells (range, 3.5–7%) and four had t(11;14) or gain 1q. λ IGVL genes were identified with BM MNC cDNA in 29 of 30 subjects (MGUS =13/13, SMM = 16/17); RT-PCR identified the one remaining SMM IGVL gene.
Of the 17 SMM patients, 10 had AL-related genes, as did 12 MGUS patients, all 22 of whom were screened for AL with tissue biopsies (Table 2). The other 8 subjects of the 30 were asymptomatic and had marrows that were negative for amyloid, but they were not screened with other tissue biopsies. AL was found in 3 SMM patients and no others, as summarized in Figure 1.
AL-related IGVL genes were found in 22 subjects. Analysis using a two-tailed Fisher’s exact test of SMM compared to MGUS shows a trend toward significance (3/10 vs. 0/12; p = 0.08). When using AL-related IGVL genes, SMM, and t(11;14) or gain 1q—found in 6 subjects, including 3 ultimately discovered to have AL—the result achieved statistical significance (3/6 vs. 0/16; p < 0.05, Fisher’s exact, two-tailed). In contrast, examining SMM with t(11;14) or gain 1q alone did not reach significance (3/11 vs. 0/6; p > 0.05). Although these statistical findings are modest, it is important to note that the exploratory nature of this study helped establish testable hypotheses and variables for developing a likelihood algorithm to detect AL in SMM subjects.

3.3. Subjects Found to Have AL

The three subjects with AL had LV2-23 in one case and LV3-1 in the other two. One was a 70-year-old man from New York with a recent diagnosis (within 1 month) of SMM with t(11;14), who presented with penile ecchymoses and was found to have AL λ-type by fat pad aspirate and mass spectrometry. Upon diagnosis, he had cardiac stage II involvement with an N-terminal prohormone brain natriuretic peptide (NT-proBNP) level of 1916 pg/mL but was asymptomatic. He received Daratumumab-based therapy and achieved a complete hematologic response with a decrease in NT-proBNP to 1066 pg/mL. The second patient, a 60-year-old man from Tennessee, had peripheral neuropathy and a 127-month history of SMM with t(11;14). Amyloid was detected in his abdominal fat, but the sample was insufficient for typing. He was treated with venetoclax-based therapy and achieved a complete response within a year, along with subjective improvement in his peripheral sensory neuropathy. The third subject was a 71-year-old woman from California with a 17-month history of SMM, t(11;14), and marrow findings consistent with λ-type amyloid, prompting further evaluation. Her NT-proBNP was 809 pg/mL, and cardiac MRI showed findings consistent with amyloid cardiomyopathy. She received daratumumab-based therapy, with venetoclax added after a sub-optimal response, followed by a stem-cell transplant with 140 mg/M2 of melphalan. She subsequently achieved a cardiac response and a reduction in FLC from 888 to 84 mg/L. No MGUS patients were found to have AL. One SMM patient (with LV1-44) progressed to MM requiring therapy.

3.4. Marrow Mononuclear Cells (MNC)

From 2 × 106 marrow MNC, we obtained 1108 ng/μL cDNA (540–2299) and from CD138-selected cells we obtained 1184 ng/μL (484–1986). We sent 60 μL of each sample in blinded fashion to CUIMC. The privacy and confidentiality standards were stringent and highlighted on the informed consent document. The IGVL genes identified in both samples matched for all patients, although the number of CDR3 reads were higher using CD138-selected cell cDNA with a mean (±SD) of 5.3 ± 2.9 × 104 compared to 3.9 ± 2.6 × 104 using MNC cDNA (p << 0.01, paired t test, two-tailed). In the 17 SMM cases, NGS was non-productive in one case with both MNC and CD138-selected cell cDNA; RT-PCR identified the clonal gene. A single IGVL gene was identified in MNC cDNA in 15, and both LV1-44 and LV1-47 were amplified in 1 case with reads of 21,683 for the former and 67,886 for the latter and similar findings with CD138-selected cell cDNA. In 10 of 13 MGUS cases, one IGVL gene was identified in MNC cDNA, while in two cases, 2 genes were amplified with different CDR3 regions, and in another case, 3 were amplified (ranked by Reads LV1-44 > LV3-19 > LV10-54). The implications of monoisotypic multiclonal gammopathies are not known. In conclusion, CD138-selection was not needed to identify the clonal genes in these cases; marrow mononuclear cells were sufficient.

4. Discussion

Earlier detection of AL remains an unmet need [10]. Advances in order to meet this need will involve determining the likelihood or risk of AL in patients with monoclonal gammopathies, such as SMM. In SMM, 23% of patients have t(11;14) and 30% had gain 1q [6,19,20,21]. In a series of 133 AL patients whose marrow plasma cells were evaluated for clonal cytogenetic abnormalities, 83 (62%) had t(11;14) and 35 of 130 (27%) had gain 1q [15]. In another series of 140 AL patients, 59% had t(11;14) and 20% had gain 1q [22]. On average, 60% of AL cases are t(11;14) and 29% are gain 1q. The t(11;14) translocation, deleting the heavy chain locus, likely accounts for the high frequency of FLC-producing clones in AL [18,23].
In addition to at least 75% of AL patients having either t(11;14) or gain 1q, there is a 3:1 λ isotype predominance and relatively restricted λ IGVL gene usage [12,24]. Among the 33 λ IGVL germline genes on chr 22q11.2, nine accounted for 93% of the AL λ-type IGVL sequences in the Boston University database in 2020 (579 of 620), and 87% of the λ IGVL sequences in the Mayo Clinic report based on biopsy-derived protein sequences from patients (371 of 428) [12,24]. At the start of this study, we designated these 9 genes (LV6-57, LV2-14, LV1-44, LV3-1, LV1-51, LV3-21, LV3-19, LV2-23, LV1-40) as being related to AL λ-type. In a prior internet-based screening study, we identified two cases of AL requiring therapy in 21 patients with λ monoclonal gammopathies who were screened based on IGVL gene identification (both were SMM and had LV2-14) [12]. Recently, AL-Base has been updated to include over 2000 monoclonal light-chain sequences from myeloma, AL, and other plasma cell dyscrasias. Sixteen germline sequences (12 λ and 4κ) were significantly associated with AL compared to myeloma and other sequences, including LV2-23 and LV3-1, the IGVL genes found in the three AL patients identified in this study [25].
In this multicenter study, we used age, the FLC criterion of a dFLC > 23 mg/L, and the presence of AL-related IGVL genes to evaluate the screening results for the presence of AL in patients with λ SMM and MGUS. Twenty-two of thirty subjects who met the age and FLC criteria had AL-related IGVL genes and were screened for AL with tissue biopsies. This raises a question regarding the utility of AL-related IGVL genes as a selection variable; however, as the contingency table analyses above suggest, IGVL germline gene use in AL may be a key variable to include when attempting to create a likelihood algorithm for AL in SMM patients. Of note, a recent re-evaluation of AL-Base that included a significantly increased number of IGVL sequences from myeloma patients concluded that 8 of the 9 genes we determined were AL-related were significantly over-represented in AL compared to multiple myeloma [25]. Moreover, our study confirms that marrow mononuclear cells shipped overnight to a central facility were adequate for the molecular identification of IGVL genes by next generation sequencing without the need for a CD138-selection step.
The additional variable NT-proBNP, not collected in this study, may provide further predictive power to a likelihood algorithm [26]. A larger study, in addition to adding NT-proBNP, could also focus on subjects with SMM of both isotypes, κ and λ, with FLC gene identification for both isotypes; exclude MGUS; lower the age for eligibility; and employ tissue testing for AL upon enrollment of all subjects with SMM and dFLC > 23 mg/L. Screening for AL κ-type in subjects with SMM increases the complexity of NGS. There are more κ IGVL genes (about 40) than λ, and the AL κ-type repertoire is less restricted. But, primers and methods are available [27]. In SMM, 70% of patients have κ-type serum M-proteins, with 53% employing KV1 family genes, although the frequency is only 50% for those with Bence−Jones proteinuria containing light chains [28,29]. In contrast, 67% of AL κ-type employ KV1 genes. In systemic AL cases reported by investigators at Mayo Clinic, there were 185 κ-type, 124 (67%) of which were KV1; KV3-15 and KV4-01 accounted for 33 of the remaining cases. In that data set, KV1-16, KV1-33, and KV1-39 accounted for 69 (56%) of KV1 cases [24]. In AL-Base, KV1-16 and KV1-33 accounted for 10% and 40%, respectively, of KV1 AL genes. In our original assessment of IGVL genes and organ tropism, all 12 κ cases were KV1 family members [30]. For a large study, we could reasonably consider KV1 genes and KV3-15 and KV4-01 as AL-related since they accounted for 85% of AL κ-type cases in the Mayo data set [24]. Another consideration involves the use of the dFLC of 23 mg/L; 29 of the 30 cases we reported had abnormal ratios, but of course these cases were all λ. Given the changes in the ratio that occur with renal insufficiency, which affect κ light-chain measurements, it is likely more appropriate to use the dFLC based on the DoD data [10,16].
In addition to the use of biomarkers for screening, the evaluation of cardiac involvement in patients diagnosed with AL—such as the case of the 71-year-old woman described above and the 59-year-old woman with SMM for 9 years who was found to have cardiac involvement with AL in our first screening study—requires both advanced echocardiography and often cardiac magnetic resonance imaging [31,32,33].
Major limitations of our study are that the sample size is small and that not all subjects were screened for AL. The latter limitation clearly may have introduced bias and underestimated the presence of AL in this small sample. Nevertheless, in this exploratory study, the cases are drawn from multiple centers across the country and the identification of three cases of AL in patients with SMM, t(11;14) and predefined AL-related IGVL genes supports the pursuit of a larger study (Table 3). All three patients with AL in this study were treated and achieved hematologic responses and clinical improvement. Notably, all three AL patients had SMM, as did the two patients in our prior online study, which guided us in the design of a larger study considering SMM instead of MGUS subjects (R01-CA279808) [12].
Early diagnosis of AL may require the creation of novel approaches such as electron microscopy for light-chain ‘seeds’ in surrogate biopsies or the imaging of amyloid with agents such as 18F-florbetapir or designer peptides [34,35]. The latter may enable imaging similar to radioactive pyrophosphate scans used for diagnosing hereditary and wild-type transthyretin cardiac amyloidosis without need for a biopsy [36]. A screening model such as the one proposed here may also be useful as an initial step before expensive imaging studies. A similar model for Alzheimer’s disease (AD) is the PrecivityAD test for beta-amyloid and for Apo E isoform-specific prototyping, which has been approved by the FDA as a screening test to assist in identifying relative risk of AD and in selecting patients for expensive 18F-florbetapir scans [37]. Finally, our results support the relevance of using the following parameters in developing a likelihood algorithm for AL or risk of AL in SMM patients: a dFLC of > 23 mg/L (based on the DoD cases), the presence of t(11;14) or gain 1q, NT-pro BNP > 332pg/mL and AL-related IGVL genes.

Author Contributions

Conceptualization, R.L.C.; Formal analysis, R.L.C.; Resources, L.X.L., S.W.W., A.C., S.A.T., T.F., N.C.L., C.V. and S.L.; Data curation, P.Z., M.M.M., R.Y., J.L., H.X., L.K., J.P., S.S. and X.M.; Writing—original draft, R.L.C.; Writing—review & editing, P.Z., D.T., L.X.L., S.W.W., A.C., S.A.T., T.F., N.C.L., C.V. and S.L.; Project administration, D.T.; Funding acquisition, R.L.C. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by NIH/National Institute of Aging grant R21-AG070502 (RLC), by R01-CA279808 (RC), and by the Janssen QuickFire Challenge Idea Grant. For their continued support of the Tufts Medicine Myeloma and Amyloid Research Fund, we thank all of the donors including the Sidewater Family Fund, the Amyloidosis Foundation, David and Barbara Levine (in memoriam), Mackenzie’s Mission and the Demarest Lloyd Jr. Foundation. We also thank the patients and their families across the USA and the clinical research coordinators who contributed to this study.

Institutional Review Board Statement

The Health Sciences Institutional Review Board (HS IRB) at Tufts Medical Center approved our multicenter study titled “Screening to Improve Survival in AL Amyloidosis” (Approval number: STUDY00000858). Recruitment started on 28 August 2020 and ended on 7 June 2023. Participants were required to provide written informed consent in order to participate.

Informed Consent Statement

All subjects provided written informed consent to the study and to the reporting of de-identified results.

Data Availability Statement

The data that support the findings of this study are openly available in the Harvard Dataverse at https://doi.org/10.7910/DVN/RI83WG (accessed on 3 June 2025). This study was posted on ClinicalTrials.gov (NCT04615572).

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Kastritis, E.; Palladini, G.; Minnema, M.C.; Wechalekar, A.D.; Jaccard, A.; Lee, H.C.; Sanchorawala, V.; Gibbs, S.; Mollee, P.; Venner, C.P.; et al. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N. Engl. J. Med. 2021, 385, 46–58. [Google Scholar] [CrossRef] [PubMed]
  2. Varga, C.; Comenzo, R.L. High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: A comprehensive review. Bone Marrow Transplant. 2019, 54, 508–518. [Google Scholar] [CrossRef] [PubMed]
  3. Bianchi, G.; Zhang, Y.; Comenzo, R.L. AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021, 3, 467–487. [Google Scholar] [CrossRef] [PubMed]
  4. Kyle, R.A.; Remstein, E.D.; Therneau, T.M.; Dispenzieri, A.; Kurtin, P.J.; Hodnefield, J.M.; Larson, D.R.; Plevak, M.F.; Jelinek, D.F.; Fonseca, R.; et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 2007, 356, 2582–2590. [Google Scholar] [CrossRef]
  5. Lousada, I.; Comenzo, R.L.; Landau, H.; Guthrie, S.; Merlini, G. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv. Ther. 2015, 32, 920–928. [Google Scholar] [CrossRef]
  6. Neben, K.; Jauch, A.; Hielscher, T.; Hillengass, J.; Lehners, N.; Seckinger, A.; Granzow, M.; Raab, M.S.; Ho, A.D.; Goldschmidt, H.; et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J. Clin. Oncol. 2013, 31, 4325–4332. [Google Scholar] [CrossRef]
  7. Maurer, M.S.; Elliott, P.; Comenzo, R.; Semigran, M.; Rapezzi, C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation 2017, 135, 1357–1377. [Google Scholar] [CrossRef]
  8. McCausland, K.L.; White, M.K.; Guthrie, S.D.; Quock, T.; Finkel, M.; Lousada, I.; Bayliss, M.S. Light Chain (AL) Amyloidosis: The Journey to Diagnosis. Patient 2018, 11, 207–216. [Google Scholar] [CrossRef]
  9. Gertz, M.A. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am. J. Hematol. 2018, 93, 1169–1180. [Google Scholar] [CrossRef]
  10. Weiss, B.M.; Hebreo, J.; Cordaro, D.V.; Roschewski, M.J.; Baker, T.P.; Abbott, K.C.; Olson, S.W. Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J. Clin. Oncol. 2014, 32, 2699–2704. [Google Scholar] [CrossRef]
  11. Comenzo, R.L. Plasma cell neoplasms, their precursor States, and their prediction of organ damage. J. Clin. Oncol. 2014, 32, 2679–2682. [Google Scholar] [CrossRef] [PubMed]
  12. Zhou, P.; Mansukhani, M.M.; Yeh, R.; Lu, J.; Xia, H.; Koganti, L.; Pang, J.; Toskic, D.; Scalia, S.; Ma, X.; et al. Seeking Amyloidosis Very Early: Free light Chain Difffferentials and IGLV Gene Use as Screening Variables for Light-chain Amyloidosis in λ Monoclonal Gammopathies. Br. J. Cancer 2024, 7, 681–686. [Google Scholar]
  13. Muchtar, E.; Gertz, M.A.; Kyle, R.A.; Lacy, M.Q.; Dingli, D.; Leung, N.; Buadi, F.K.; Hayman, S.R.; Kapoor, P.; Hwa, Y.L.; et al. A Modern Primer on Light Chain Amyloidosis in 592 Patients with Mass Spectrometry-Verified Typing. Mayo Clin. Proc. 2019, 94, 472–483. [Google Scholar] [CrossRef] [PubMed]
  14. Tahir, U.A.; Doros, G.; Kim, J.S.; Connors, L.H.; Seldin, D.C.; Sam, F. Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. Sci. Rep. 2019, 9, 8552. [Google Scholar] [CrossRef]
  15. Palladini, G.; Dispenzieri, A.; Gertz, M.A.; Kumar, S.; Wechalekar, A.; Hawkins, P.N.; Schonland, S.; Hegenbart, U.; Comenzo, R.; Kastritis, E.; et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes. J. Clin. Oncol. 2012, 30, 4541–4549. [Google Scholar] [CrossRef]
  16. Hutchison, C.A.; Basnayake, K.; Cockwell, P. Serum free light chain assessment in monoclonal gammopathy and kidney disease. Nat. Rev. Nephrol. 2009, 5, 621–628. [Google Scholar] [CrossRef]
  17. Zhou, P.; Ma, X.; Iyer, L.; Chaulagain, C.; Comenzo, R.L. One siRNA pool targeting the lambda constant region stops lambda light-chain production and causes terminal endoplasmic reticulum stress. Blood 2014, 123, 3440–3451. [Google Scholar] [CrossRef]
  18. Bodi, K.; Prokaeva, T.; Spencer, B.; Eberhard, M.; Connors, L.H.; Seldin, D.C. AL-Base: A visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences. Amyloid 2009, 16, 1–8. [Google Scholar] [CrossRef]
  19. Gonzalez, D.; van der Burg, M.; Garcia-Sanz, R.; Fenton, J.A.; Langerak, A.W.; Gonzalez, M.; van Dongen, J.J.; San Miguel, J.F.; Morgan, G.J. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007, 110, 3112–3121. [Google Scholar] [CrossRef]
  20. Wu, V.; Moshier, E.; Leng, S.; Barlogie, B.; Cho, H.J.; Jagannath, S.; Madduri, D.; Mazumdar, M.; Parekh, S.; Chari, A. Risk stratification of smoldering multiple myeloma: Predictive value of free light chains and group-based trajectory modeling. Blood Adv. 2018, 2, 1470–1479. [Google Scholar] [CrossRef]
  21. Schmidt, T.M.; Fonseca, R.; Usmani, S.Z. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021, 11, 83. [Google Scholar] [CrossRef]
  22. Bochtler, T.; Hegenbart, U.; Kunz, C.; Benner, A.; Kimmich, C.; Seckinger, A.; Hose, D.; Goldschmidt, H.; Granzow, M.; Dreger, P.; et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: A long-term follow-up study. Blood 2016, 128, 594–602. [Google Scholar] [CrossRef] [PubMed]
  23. Zhou, P.; Hoffman, J.; Landau, H.; Hassoun, H.; Iyer, L.; Comenzo, R.L. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clin. Lymphoma Myeloma Leuk. 2012, 12, 49–58. [Google Scholar] [CrossRef] [PubMed]
  24. Kourelis, T.V.; Dasari, S.; Theis, J.D.; Ramirez-Alvarado, M.; Kurtin, P.J.; Gertz, M.A.; Zeldenrust, S.R.; Zenka, R.M.; Dogan, A.; Dispenzieri, A. Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry. Blood 2017, 129, 299–306. [Google Scholar] [CrossRef] [PubMed]
  25. Morgan, G.J.; Nau, A.N.; Wong, S.; Spencer, B.H.; Shen, Y.; Hua, A.; Bullard, M.J.; Sanchorawala, V.; Prokaeva, T. An updated AL-base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis. Amyloid 2024, 32, 129–138. [Google Scholar] [CrossRef]
  26. Merlini, G.; Lousada, I.; Ando, Y.; Dispenzieri, A.; Gertz, M.A.; Grogan, M.; Maurer, M.S.; Sanchorawala, V.; Wechalekar, A.; Palladini, G.; et al. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia 2016, 30, 1979–1986. [Google Scholar] [CrossRef]
  27. Schanz, M.; Liechti, T.; Zagordi, O.; Miho, E.; Reddy, S.T.; Gunthard, H.F.; Trkola, A.; Huber, M. High-throughput sequencing of human immunoglobulin variable regions with subtype identification. PLoS ONE 2014, 9, e111726. [Google Scholar] [CrossRef]
  28. Kyle, R.A.; Larson, D.R.; Therneau, T.M.; Dispenzieri, A.; Melton, L.J., 3rd; Benson, J.T.; Kumar, S.; Rajkumar, S.V. Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): A retrospective cohort study. Lancet Haematol. 2014, 1, e28–e36. [Google Scholar] [CrossRef]
  29. Blum, A.; Bazou, D.; O’Gorman, P. Smoldering multiple myeloma: Prevalence and current evidence guiding treatment decisions. Blood Lymphat. Cancer 2018, 8, 21–31. [Google Scholar] [CrossRef]
  30. Comenzo, R.L.; Zhang, Y.; Martinez, C.; Osman, K.; Herrera, G.A. The tropism of organ involvement in primary systemic amyloidosis: Contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 2001, 98, 714–720. [Google Scholar] [CrossRef]
  31. de Gregorio, C.; Trimarchi, G.; Faro, D.C.; De Gaetano, F.; Campisi, M.; Losi, V.; Zito, C.; Tamburino, C.; Di Bella, G.; Monte, I.P. Myocardial Work Appraisal in Transthyretin Cardiac Amyloidosis and Nonobstructive Hypertrophic Cardiomyopathy. Am. J. Cardiol. 2023, 208, 173–179. [Google Scholar] [CrossRef] [PubMed]
  32. de Gregorio, C.; Trimarchi, G.; Faro, D.C.; Poleggi, C.; Teresi, L.; De Gaetano, F.; Zito, C.; Lofrumento, F.; Koniari, I.; Licordari, R.; et al. Systemic Vascular Resistance and Myocardial Work Analysis in Hypertrophic Cardiomyopathy and Transthyretin Cardiac Amyloidosis with Preserved Left Ventricular Ejection Fraction. J. Clin. Med. 2024, 13, 1671. [Google Scholar] [CrossRef] [PubMed]
  33. Licordari, R.; Trimarchi, G.; Teresi, L.; Restelli, D.; Lofrumento, F.; Perna, A.; Campisi, M.; de Gregorio, C.; Grimaldi, P.; Calabro, D.; et al. Cardiac Magnetic Resonance in HCM Phenocopies: From Diagnosis to Risk Stratification and Therapeutic Management. J. Clin. Med. 2023, 12, 3481. [Google Scholar] [CrossRef]
  34. Dorbala, S.; Ando, Y.; Bokhari, S.; Dispenzieri, A.; Falk, R.H.; Ferrari, V.A.; Fontana, M.; Gheysens, O.; Gillmore, J.D.; Glaudemans, A.; et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization. J. Nucl. Cardiol. 2019, 14, e000029. [Google Scholar] [CrossRef]
  35. Varga, C.; Dorbala, S.; Lousada, I.; Polydefkis, M.J.; Wechalekar, A.; Maurer, M.S.; Comenzo, R.L. The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types. Blood Rev. 2021, 45, 100720. [Google Scholar] [CrossRef]
  36. Gillmore, J.D.; Maurer, M.S.; Falk, R.H.; Merlini, G.; Damy, T.; Dispenzieri, A.; Wechalekar, A.D.; Berk, J.L.; Quarta, C.C.; Grogan, M.; et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016, 133, 2404–2412. [Google Scholar] [CrossRef]
  37. Kirmess, K.M.; Meyer, M.R.; Holubasch, M.S.; Knapik, S.S.; Hu, Y.; Jackson, E.N.; Harpstrite, S.E.; Verghese, P.B.; West, T.; Fogelman, I.; et al. The PrecivityAD test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis. Clin. Chim. Acta 2021, 519, 267–275. [Google Scholar] [CrossRef]
Jcm 14 04146 g001
Figure 1. Screening Schema.
Figure 1. Screening Schema.
Jcm 14 04146 g001
Table 1. Baseline characteristics of subjects in NCT04615572 (n = 30).
Table 1. Baseline characteristics of subjects in NCT04615572 (n = 30).
AgeCharacteristic
Median (range) years69 (58–92)
Distribution—no. (%)
<65 y7 (23)
≥65 y23 (77)
Sex, no. (%)
Male19 (63)
Female11 (37)
Median months from SMM diagnosis to enrollment13 (1–132)
Median serum creatinine (normal 0.55–1.3 mg/dL)1.0 (0.60–3.08)
Median alkaline phosphatase (normal 30–130 U/L)81 (37–180)
MGUS/SMM (n)13/17
MGUS
Median iFLC (mg/L)326 (42–1328)
Median FLC ratio0.11 (0.02–0.30)
t(11;14) (number)1
gain 1q21 (number)3
SMM
Median iFLC (mg/L)201 (83–1040)
Median FLC ratio0.06 (0.01–0.26)
t(11;14) (number)6
gain 1q21 (number)6 *
* One subject had both t(11;14) and gain 1q. Total patients was 11.
Table 2. NGS IGVL gene identifications in λ SMM subjects.
Table 2. NGS IGVL gene identifications in λ SMM subjects.
SMM IGVLNCT04615572
(n = 17 SMM)		GenBank #
LV1-442OQ912884
OQ912876
LV1-472OQ884472
OR506910
LV2-83OQ912883
OQ912886
OQ912887
LV2-111OQ912882
LV2-141OQ912877
LV2-232 (1 AL)OR506909
OQ912881
LV3-13 (2 AL)OQ819165
OQ912879
OQ912885
LV3-121OQ912875
LV3-212OQ912880
OQ912878
Table 3. Characteristics of the SMM subjects who had AL-related IGVL genes.
Table 3. Characteristics of the SMM subjects who had AL-related IGVL genes.
Age/SexSMMdFLC>23mg/LAL-Related Genet(11;14) or Gain 1qALAL Cardiac *
70M√√√√√√
60M√√√√√
71F√√√√√√
73M√√√√
67M√√√√
65M√√√√
92M√√
66M√√
67M√√
* NT-proBNP > 332pg/mL. √ = present.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zhou, P.; Mansukhani, M.M.; Yeh, R.; Lu, J.; Xia, H.; Koganti, L.; Pang, J.; Toskic, D.; Scalia, S.; Ma, X.; et al. Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies. J. Clin. Med. 2025, 14, 4146. https://doi.org/10.3390/jcm14124146

AMA Style

Zhou P, Mansukhani MM, Yeh R, Lu J, Xia H, Koganti L, Pang J, Toskic D, Scalia S, Ma X, et al. Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies. Journal of Clinical Medicine. 2025; 14(12):4146. https://doi.org/10.3390/jcm14124146

Chicago/Turabian Style

Zhou, Ping, Mahesh M. Mansukhani, Raymond Yeh, Jiesheng Lu, Hongai Xia, Lahari Koganti, Jiuhong Pang, Denis Toskic, Stephanie Scalia, Xun Ma, and et al. 2025. "Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies" Journal of Clinical Medicine 14, no. 12: 4146. https://doi.org/10.3390/jcm14124146

APA Style

Zhou, P., Mansukhani, M. M., Yeh, R., Lu, J., Xia, H., Koganti, L., Pang, J., Toskic, D., Scalia, S., Ma, X., Lee, L. X., Wong, S. W., Chung, A., Tuchman, S. A., Fogaren, T., Coady Lyons, N., Varga, C., Lentzsch, S., & Comenzo, R. L. (2025). Screening for Systemic Light-Chain Amyloidosis in Patients Over 60 with λ Monoclonal Gammopathies. Journal of Clinical Medicine, 14(12), 4146. https://doi.org/10.3390/jcm14124146

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop